Hans‐peter Gerber
#145,868
Most Influential Person Now
Hans‐peter Gerber's AcademicInfluence.com Rankings
Download Badge
Biology
Why Is Hans‐peter Gerber Influential?
(Suggest an Edit or Addition)Hans‐peter Gerber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The biology of VEGF and its receptors (2003) (9029)
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) (2410)
- VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation (1999) (2004)
- HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation (2003) (1651)
- Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway (1998) (1643)
- Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. (2003) (1224)
- Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* (1998) (1033)
- HIF-1alpha is essential for myeloid cell-mediated inflammation. (2003) (958)
- VEGF is required for growth and survival in neonatal mice. (1999) (930)
- Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. (2007) (896)
- Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells (2007) (863)
- Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes (1997) (844)
- VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism (2002) (723)
- Vascular endothelial growth factor is essential for corpus luteum angiogenesis (1998) (667)
- Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 (2003) (647)
- Corneal avascularity is due to soluble VEGF receptor-1 (2006) (647)
- Transcriptional activation modulated by homopolymeric glutamine and proline stretches. (1994) (627)
- Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. (2005) (623)
- VEGF inhibition and renal thrombotic microangiopathy. (2008) (570)
- Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. (2004) (509)
- The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. (2006) (488)
- The Role of Vascular Endothelial Growth Factor in Angiogenesis (2002) (452)
- The hypoxic response of tumors is dependent on their microenvironment. (2003) (404)
- VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. (2002) (398)
- Angiogenesis and bone growth. (2000) (389)
- Role of VEGF-A in Vascularization of Pancreatic Islets (2003) (381)
- Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* (2006) (352)
- A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function (2001) (350)
- Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. (2005) (318)
- VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis (2004) (312)
- Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. (2000) (257)
- Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells* (1998) (248)
- CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers (2008) (245)
- Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback (2005) (236)
- A general approach to site-specific antibody drug conjugates (2014) (236)
- Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * (1998) (233)
- Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. (2006) (226)
- The role of VEGF in normal and neoplastic hematopoiesis (2002) (215)
- Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. (2000) (200)
- ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * (2002) (186)
- Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor (2004) (181)
- Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. (2004) (172)
- Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. (2004) (171)
- Renaming the DSCR1 / Adapt78 gene family as RCAN: regulators of calcineurin (2007) (163)
- RNA polymerase II C-terminal domain required for enhancer-driven transcription (1995) (153)
- Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. (2014) (149)
- Soluble FLT1 Binds Lipid Microdomains in Podocytes to Control Cell Morphology and Glomerular Barrier Function (2012) (140)
- Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. (2007) (133)
- Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments (2015) (127)
- Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma (2008) (124)
- ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. (2002) (121)
- Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma (2006) (120)
- Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies (2007) (105)
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. (2015) (105)
- A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions (2017) (105)
- Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. (2007) (104)
- Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A 1 in Vascular Endothelial Cells * (1998) (100)
- Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. (1998) (100)
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker (2008) (99)
- Mechanisms of Resistance to Antibody–Drug Conjugates (2016) (98)
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1) (2017) (97)
- The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf (2009) (94)
- Investigational antibody drug conjugates for solid tumors (2011) (90)
- Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? (2016) (90)
- The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. (2013) (90)
- Rat-to-Elephant-to-Human Transmission of Cowpox Virus (2008) (90)
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index (2008) (87)
- Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. (2009) (83)
- Anti-CD30 diabody-drug conjugates with potent antitumor activity (2008) (82)
- Advances in bispecific biotherapeutics for the treatment of cancer. (2012) (80)
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40 (2008) (79)
- Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells (2012) (76)
- Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice (2007) (70)
- Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions (2015) (69)
- Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer (2016) (68)
- Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. (2009) (65)
- Inhibition of carcinoma cell‐derived VEGF reduces inflammatory characteristics in xenograft carcinoma (2006) (59)
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach (2013) (59)
- Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis (2009) (53)
- Antibody drug-conjugates targeting the tumor vasculature (2009) (51)
- Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates (2017) (42)
- Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. (2006) (42)
- Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring (2016) (38)
- Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. (2016) (37)
- Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia (2009) (36)
- Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. (2010) (32)
- Dobutamine stress cine‐MRI of cardiac function in the hearts of adult cardiomyocyte‐specific VEGF knockout mice (2001) (31)
- A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice (2018) (26)
- CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. (2008) (25)
- C-terminal domain (CTD) of RNA-polymerase II and N-terminal segment of the human TATA binding protein (TBP) can mediate remote and proximal transcriptional activation, respectively. (1993) (25)
- The function of VEGF-A in lens development: formation of the hyaloid capillary network and protection against transient nuclear cataracts. (2009) (24)
- Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy. (2016) (20)
- PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers (2020) (20)
- Basal components of the transcription apparatus (RNA polymerase II, TATA ‐binding protein) contain activation domains: Is the repetitive c‐terminal domain (CTD) of RNA polymerase II a “Portable Enhance Domain”? (1994) (19)
- Targeting inflammatory cells to improve anti-VEGF therapies in oncology. (2010) (16)
- Abstract 4629: Tumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloads. (2013) (14)
- In vitro transcription complementation assay with miniextracts of transiently transfected COS-1 cells. (1992) (13)
- Targeting VEGF ligands and receptors in cancer (2003) (12)
- Anti-angiogenesis: biology is the foundation for therapy. (2003) (11)
- 8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. (2013) (11)
- Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab (Journal of the National Cancer Institute (2007) 99 (1232-1239)) (2008) (9)
- Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients (2017) (8)
- Intracellular targets as source for cleaner targets for the treatment of solid tumors. (2019) (8)
- Erratum: HIF-1α is essential for myeloid cell-mediated inflammation (Cell 112:5 (648)) (2003) (8)
- Expression of a human insulin-like growth factor II cDNA in NIH-3T3 cells. (1990) (8)
- The Humanized Anti-CD40 Monoclonal Antibody, SGN-40, Potentiates Chemotherapy Regimens in NHL Xenograft Models Via Pro-Apoptotic Signaling. (2007) (7)
- Vascular Endothelial Growth Factor Molecular and Biological Aspects (1999) (7)
- Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial (2018) (6)
- Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia (2020) (6)
- Abstract 1697: Therapeutic targeting the NOTCH3 receptor with antibody drug conjugates (2015) (6)
- CD40 expression on antigen presenting cells and correlation with disease severity in atopic dermatitis. (2008) (5)
- Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma. (2008) (5)
- Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth (2013) (5)
- Identification of Antigenic Targets. (2020) (5)
- Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies (2007) (4)
- Abstract 5691: Novel site-specific antibody drug conjugates based on novel amino acid incorporation technology have improved pharmaceutical properties over conventional antibody drug conjugates (2012) (4)
- Abstract 1830: Antibody-drug conjugates with modified linker-payloads overcome resistance to a trastuzumab-maytansinoid conjugate in multiple cultured tumor cell models (2014) (3)
- NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells (2021) (3)
- Abstract 2113: Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC (2016) (3)
- Americas Antibody Congress (2009) (3)
- Abstract 4837: Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells (2014) (3)
- Calicheamicin Antibody‐Drug Conjugates and Beyond (2011) (3)
- 8th Annual European Antibody Congress 2012 (2013) (3)
- Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (2022) (2)
- SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors. (2006) (2)
- Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications (2017) (2)
- 507 POSTER Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate hBU12-vcMMAE in rituximab sensitive and resistant lymphomas (2008) (2)
- TCR mimic compounds for pHLA targeting with high potency modalities in oncology (2022) (1)
- SGN-30 Macrophages contribute to the antitumor activity of the anti-CD30 antibody (2013) (1)
- Vascular Endothelial Growth Factor Antibodies for Anti-Angiogenic Therapy (2008) (1)
- Abstract 5425: An anti-Ephrin-A4 calicheamicin conjugate effectively targets triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regression (2015) (1)
- Abstract 868: Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors (2016) (1)
- Disease in Murine Collagen-Induced Arthritis Anti-CD70 Antibody Ameliorates Joint Blocking of CD27-CD70 Pathway by (2009) (1)
- Discovery of new auristatins for the use on antibody drug conjugates for the treatment of cancer (2013) (1)
- Americas Antibody Congress: September 21-23, 2009, Washington, D.C. (2009) (1)
- Abstract 1241: Targeting the IL-13 receptor alpha 2 with novel antibody-drug conjugates for the treatment of cancer. (2013) (1)
- Angiopoietin-like 4 protein inhibitor combinations and their use (2005) (0)
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach (2013) (0)
- Abstract C117: Preclinical pharmacokinetics of an antibody-drug conjugate targeting 5T4. (2011) (0)
- Abstract LBA006: Identification of novel, tumor specific pHLA targets recognized by TILs from CPI responders in a high-throughput, high-diversity pHLA library screening platform (3T-TRACE) (2021) (0)
- Abstract 1469: Patient derived xenograft (PDX) models: improving predictability of experimental cancer therapies (2015) (0)
- Secreted and transmembrane polypeptides and nucleic acids to their codes (2000) (0)
- Down syndrome critical region proteinl (DSCR1), a novel VEGF target gene that regulates expression of COX-2 on activated endothelial cells (2005) (0)
- Sa.2. Inhibition of Collagen-induced Arthritis by an Antibody Targeting CD70 (2008) (0)
- We employed two independent approaches to inactivate the angiogenic protein VEGF in newborn mice: inducible, Cre- loxP- mediated gene targeting, or administration of mFlt(1- 3)-IgG, a soluble VEGF receptor chimeric protein. Partial inhibition of VEGF achieved by inducible gene targeting (1999) (0)
- Abstract B010: Pharmacodynamics and mechanisms of drug action for bispecific redirected T cell immunotherapy against P-cadherin (2016) (0)
- Role of Vascular Targeting Agents in the Treatment of Solid Tumors Current and Future Developments (2009) (0)
- Abstract 644: Impact of conjugation site on pharmacokinetics and off-target toxicity of site-specific antibody drug conjugates (2015) (0)
- Abstract 564: The expression of fetal oncogene 5T4 in CTCs obtained from NSCLC patients is discordant with the expression measured in the primary tumor (2015) (0)
- Angiogenesis: New Opportunities and Solutions for Drug Development. Predictive markers for antiangiogenic drugs (2003) (0)
- RPE–Produced VEGF in Choriocapillaris Function (2006) (0)
- Anti-edb antibodies and antibody-drug conjugates (2017) (0)
- Abstract C161: Tumor cells selected for resistance to an antibody-drug conjugate modulate protein trafficking and signaling pathways. (2011) (0)
- Immune modulation mediated by the humanized anti‐CD70 monoclonal antibody SGN‐70 (2008) (0)
- Conjugated antibody-drug (2012) (0)
- Role of the Retinal Müller Cells in Diabetic Retinopathy (2007) (0)
- Subject Index Vol. 106, 2001 (2002) (0)
- Abstract 5471: Notch-antibody drug conjugates have a different mechanism of action than Notch signaling inhibitors and induce tumor regression. (2013) (0)
- Abstract 2530: Long-term tumor regression induced by a novel antibody drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells (2012) (0)
- 523 POSTER Combination of the anti-CD30–auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin lymphoma (2008) (0)
- Large Molecule Therapeutics Discovery & Preclinical Development Long-term Tumor Regression Induced by an Antibody – Drug Conjugate That Targets 5 T 4 , anOncofetal AntigenExpressed on Tumor-Initiating Cells (2013) (0)
- Lens VEGF-A Contributes to the Formation of the Fetal Vasculature, but Is Not Necessary for Lens Development (2003) (0)
- Protein inhibitors angiopoietin-like 4, combinations and their use. (2005) (0)
- Inducible gene-targeting reveals critical roles for VEGFR-1 and VEGFR-2 during early postnatal development in the mouse (2005) (0)
- Anti-Vascular Endothelial Growth Factor Therapy and Renal Thrombotic Microangiopathy (2017) (0)
- Inhibitors of angiopoitin-like 4 protein, combinations and uses thereof (2005) (0)
- 膵β細胞におけるVEGF-Aの役割(平成16年度順天堂大学老人性疾患病態・治療研究センター研究発表会抄録) (2005) (0)
- Abstract A215: Antitumor activity of an antibody-drug conjugate targeting 5T4, a putative tumor-initiating cell antigen. (2011) (0)
- Blockade of VEGF-A prevents mobilization and recruitment of endothelial progenitor cells (EPCs) to the tumor vasculature (2005) (0)
- Targeted ablation of human CD30 positive cells with an anti-CD30-MMAE antibody-drug conjugate (SGN-35) in vivo inhibits antigen-specific secondary immune responses (50.17) (2009) (0)
- Abstract 2476: Bispecific redirected T-cell immunotherapy targeting P-cadherin expressing tumors (2015) (0)
- 527 POSTER Improving the therapeutic window of antibody-drug conjugates through novel linker design (2008) (0)
- Abstract #3243: Dacetuzumab (SGN-40), a humanized anti-CD40 monoclonal antibody, has chemosensitization activity and improves gemcitabine efficacy in NHL xenograft models (2009) (0)
- Antibody pharmaceutical conjugates (2012) (0)
- Abstract 2669: Targeting the tumor vasculature with antibody drug conjugates (2014) (0)
- Abstract 4752: Preclinical development and translational research on a novel antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. (2013) (0)
- Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates (2017) (0)
- Abstract 1220: A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions (2016) (0)
- Abstract 578: A functional approach to identifying and engineering TCRs results in highly-potent and specific TCRs for TCR-T cell therapy (2022) (0)
- Contents Vol. 106, 2001 (2002) (0)
- 31st International Conference Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells (2014) (0)
- Abstract LB-202: Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates: mechanism and monitoring (2016) (0)
- 17th Annual Petersheim Academic Exposition Abstracts (2012) (0)
- 443 Notch3-targeted antibody drug conjugates have superior preclinical efficacy to Notch signaling inhibitors (2014) (0)
- SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML. (2007) (0)
- Abstract 2059: In situ imaging of antibody drug conjugate (ADC) binding and pharmacodynamic biomarkers of response in models of human cancer (2014) (0)
- Abstract 935: Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC) (2018) (0)
This paper list is powered by the following services:
